TECH CENTER 1600/2900

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Kn wn				
Application Number	10/087,951			
Filing Date	03/05/2002			
First Named Inventor	Donald L. Barbeau			
Art Unit	1751			
Examiner Name				
Attorney Docket Number	Barbeau 0302			

					nt 6	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
RR	US- 2,484,029	10/11/1949	Hartman et al.	1260	250	page 2,col 4; page 3, col 5	
RR	US- 3,840,539	10/08/1974	Ueno et al.	2601		page 1, col 1-2	
B 8	US- 4,061,636	12/06/1977	Wise et al.	1260K			
BIS	US- 4,757,142	06/12/1988	Pinza et al.	544/	729		
RR	US- 4,002,753	01/11/1977	Carpi et al.	4241:	250		
KR2	us- 3,978,057	08/31/1976	Anderson et al.	2601	250		
RP	US- 4,478,837	10/23/1984	Schenker	424	15 U		
	us-						
	us-		<u></u>	!		RECEIV	F
	US-						-
	US-					NOV-	
	us-					NOV 2 6 200	12
	us-						
	US-					TC 174	U
]	US-					. 10 1. 7	
	US-						
	US-						
	US-					***************************************	
	US-						
	US-	1					

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
						_	
						_	
					44	-	

Examiner Date Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

English language Translation is attracted.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

contomerates and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (options). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

TRADE

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of Sheet 2

Complete if Known				
Application Number	10/087,951			
Filing Date	03/05/2002			
First Named Inventor	Donald L. Barbeau			
Group Art Unit	1751			
Examiner Name				
Attorney Docket Number	Barbeau 0302			

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RR		DRUERY, J. AND MARXER, A. Hypotensive Hydrazinopthalines and Related Compounds, Journal of Medicinal and Pharmaceutical Chemistry 1(1): 1-21 (1959) Johnson Reprint Corporation New York
KIZ		SHEPHERD, A. et al. Hydralzine kinetics after single and repeated oral doses, Clinical Pharmacology and Therapeutics 28(6): 804-811(1980)
RR		LUDDEN, T.M. et al. Hydralazine kinetics in hypertensive patients after single intravenous administration, Clinical Pharmacology and Therapeutics 28(6): 736-742(1980)
छि		HAEGELE K.D. et al. Quantitative Analysis of Hydralzine Pyruvic Acid Hydrazone, The Major Mwetabolite of Hydralazine Journal of Chromatography 187:171-179 (1980)
RR		CLEMENTI, W.A. et al. Endogenous Generation of Hydralazine form Labile Hydralazine Hydrazones, Journal of Pharmacology and Experimental Therapeutics 222(1):159-165 (1982)
ras		OGISO, T. et al. Pharmacokinetics of Formation and Excretion of Some Metabolites of Hydralazine and Their Hypotensive Effect in Rats, Journal of Pharmacology and Experimental Therapeutics 233(2):485-490 (1985)
rere		IWAKI, M. et al. In Vitro Kinetic Studies of the Reaction of Hydralazine and its Acetone Hydrazone with Pyruvic Acid, Journal of Pharmaceutical Sciences 77(3):280- 283 (1988)
np		McLEAN, A.J. et al. Interaction of Hydralazine and Hydrazone Derivatives with Contractile Mechanisms in Rabbit Aoartic Smooth Muscle, Journal of Pharmacology and Experimental Therapeutics 205(2): 418-425 (1978)
1517		HAEGELE, K.D. et al. Identification of Hydrallazine and Hydrallazine Hydrazone Metabolites in Human Body Fluids and In Vitro Comparisons of their Smooth Muscle Activity British, Journal of Clinical Pharmacology 5:489-494 (1978)
uh		BARRON, K. et al. Comparative Evaluation of the in vitro Effects of Hydralazine and Hydralazine Acetonide on Arterial Smooth Muscle, British Journal of Pharmacology 621:345-349 (1977)
RK		ISRAILI, Z.H. and DAYTON, P.G. Metabolism of Hydralazine Drug, Metabolism Reviews 6(2):283-305 (1977)

Examiner	00	Date 1 7.01/	
Signature	1 Cumul	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO 10/087,951 **Application Number** INFORMATION DISCLOSURE 03/05/2002 Filing Date Donald L. Barbeau STATEMENT BY APPLICANT First Named Inventor 1751 Group Art Unit **Examiner Name** (use as many sheets as necessary) Attorney Docket Number Barbeau 0302 3 of Sheet

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
ķΩ		O'DONNELL, J.P. et al. Kinetic Studies of Hydralazine Reaction with Acetaldehyde, Journal of Pharmaceutical Sciences 68(10): 1256-1258(1979)
P		ZIMMER, H., A Major Metabolit of 1-Hydrazinophthalazine, Arzeim-Forsch 20(10):1586-1587 (1970)
RN		TALSETH, T. Pharmacokinetics and Cardiovascular Effects in Rabbits of a Major Hydralazine Metabolite, the Hydralzine Pyruvic-Acid Hydrazone 211(3):509- 513 (1979)
RP		McLEAN,A.J. et al. Study of In Vitro Effects of Hydralazine Metabolites -Comparative Evaluation of Products of Hydroxylation, Hydrolysis and Conjguation, Archives Instrnational Pharmacodynamics 235:19-25 (1978)
RP		LaCAGNIN, L.B. et al. Metabolic Activation of Hydralazine by Rat Liver Microsomes, Biochemical Pharmacology 36(16): 2667-2672 (1987)
RR		LESSEN, T. A et al. Interactions between Drug Substances and Excipients. 1. Fluorescence and HPLC Studies of Triazophthalazine Derivativces from Hydralazine Hydrochloride and Starch Journal of Pharmaceutical Sciences 85(3): 326-329 (1996)
RIT		SCHNECK,D.W. et al. Plasma levels of free and acid-labile hydralazine: Effects of multiple dosing and of procainamide Clinical Pharmacology and Therapeutics 24(6): 714-719 (1978)
RR		TALSETH T. et al. Hypotensive Effect of the Hydralazine-Acetone Hydrazone in Conscious Rabbits: Evidence for its Back-Conversion to Hydralazine In Vivo , Journal of Cardiovascular Pharmacology 4: 370-374 (1982)
KK		McLEAN, A.J. et al. Comparative Evaluation of the Hypotensive Activity of Two Major Metabolites of Hydralazine (1-Hydrazinophthalazine) European Journal of Drug Metabolism and Pharmacokinetics 1: 17-20 (1977)
NR		JUCHAU, M.R. AND HORITA, A. Metabolism of Hydralazine Derivatives of Pharmacological Interest, Drug Metabolism Reviews 1(1): 71-100 (1972)
ירוץ		HAEGELE, K.D. et al. Determination of Hydralazine and its Metabolites by Gas Chromatography-Mass Spectrometry Journal of Chromatography 126:517-534 (1976)

A STATE OF THE PARTY OF THE PAR		The second secon	The second secon
Examiner Signature	1 Coupred	Date Considered	1-7-04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO			i i	Complete if Known		
			LOCUE	Application Number	10/087,951	
INFOR	KMAHON	A DISC	LOSURE	Filing Date	03/05/2002	
STAT	EMENT I	RY AP	PLICANT	First Named Inventor	Donald L. Barbeau	
VIAI	-141-141	W 1 /11	LIOAN	Group Art Unit	1751	
	(use as many s	sheets as ne	ecessary)	Examiner Name		
Sheet	4	of	4	Attorney Docket Number	Barbeau 0302	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ltem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RR		LUDDEN et al, High-Pressure Liquid Chromatography Assay for Hydralazine in Human Plasma, Journal of Pharmaceutical Sciences 63(11) 1423-1425(1979)	
RP		O'DONNELL, J.P., et al., High-Pressure Liquid Chromatography Studies of Reaction of Hydralazine in with Biogenic Aldehydes and Ketones, Journal of Pharmaceutical Sciences 68(12) 1524-1526(1979)	
mz		REECE, P.A., et al. Selective High-Performance Liquid Chromatographic Assays for Hydralazine and it Metabolites in Plasma of Man, Journal of Chromatography 181:427-440 (1980)	
R		LACAGNIN, L.B. Separation and Quantitation of Hydralazine Metabolites by High-Performance Liquid Chromatogaphy, Journal of Chromatography 377:319-327 (1986)	
145		IWAKA, M. ET AL. Pharmacokinetics and Biotranformation of Hydralazine Acetone Hydrazone, a Metabolite of Hydralazine, in the Rat , Journal of Pharmaceutical Sciences 78(10):867-873(1989)	
RR		KANAZAWA, H. et al. New Degradation Products in an Aqueous Solution of Hydralazine Hydrochloride with Cimetidine, Chem. Pharm. Bull. 34(4(:1840-1842 (1986)	
las.		SCHULER, W. AND WYSS, E., Zur Frage Der Spezifitat Der Wirkung Blutdrucksenkender Und Rerpinpin-AntagonistichArch. int. Pharmacodyn. CXXVIII(3-4):431-468 (1960)	
			E
			2
			_

Examiner 10 1/0 m	and	Date	1-7-01
Signature	91.1	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.